ArticleTransfusion2026
An international study on emerging arboviral infections and blood safety.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging and re-emerging arboviral infections are a risk to blood safety. We conducted an international survey on how blood establishments respond to current and future arbovirus threats. STUDY DESIGN AND
methodsA questionnaire on arbovirus donor deferral strategies, pathogen reduction, and donation screening was distributed to members of the International Society of Blood Transfusion working party on transfusion-transmitted infectious diseases. Data from 2024 were gathered and analyzed.
resultsA total of 23 survey responses were received from 21 countries. This covered a population of 1.45 billion people and 29.9 million blood donations collected in 2024. All respondents applied travel-based donor deferrals, whereas pathogen reduction, implemented by half of the respondents, was mostly applied for a selection of plasma and platelet donations. West Nile virus (WNV) was the only arbovirus blood donations were screened for by nine respondents from eight countries, with 256 donations confirmed as WNV RNA-positive in 2024. No transfusion-transmitted WNV infections were reported. DISCUSSION: Blood safety measures remain limited and unevenly distributed globally, and in their present form, are unlikely to provide protection against the growing range of emerging arboviruses. Donor deferral may not always be a sustainable blood safety strategy alone for all blood operators, due to large-scale outbreaks associated with these viruses. While pathogen reduction methodologies are being developed to be applied to all blood components, risk assessments for (re)-emerging arboviruses, such as dengue, chikungunya, and Zika viruses, should be performed to determine if additional mitigation, such as blood donation screening, is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.